Company: AZN
Filing Date: 2025-06-13
Form Type: 6-K
Source: 0001654954-25-006914
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-06-13
Form: 6-K
Chunk 0
---
#### FORM 6-K
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________</div>

#### AstraZeneca PLC
<div align='center'>INDEX TO EXHIBITS</div>

#### 1.

#### AstraZeneca enters into collaboration with CSPC
13 June 2025

<div align='center'>**AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research**</div>

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.

Under the terms of the agreement, AstraZeneca and CSPC agree to discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases.

Sharon Barr, Executive Vice President and Head of BioPharmaceuticals R&D said: "This strategic research collaboration